Chronic kidney disease (CKD) typically evolves over many years, characterized by a latent interval during which the disease is clinically silent and is detected through diagnostic testing. Currently, clinical detection and management of kidney disease is primarily performed using biomarkers that assess kidney function. The limitations of available biomarkers have prompted the establishment of the CKD Biomarkers Consortium (CKD Biocon) to pursue the discovery and validation of novel biomarkers for CKD. The consortium consists of investigators who specialize in clinical nephrology, epidemiology, molecular biology, genomics, proteomics, metabolomics, systems biology, laboratory medicine, biostatistics, and laboratory test verification and qualification. Studies conducted by the CKD Biocon assay biospecimens and analyze data from various epidemiological studies of kidney disease that were previously conducted by the NIDDK, such as the AASK, MDRD, ARIC, CRIC, DCCT/EDIC cohorts, and more. Specific aims vary by study, but include identifying and evaluating biomarkers of CKD incidence, cardiovascular events, changes in kidney histology, and disease progression and outcomes. The development and validation of biomarkers that results from these studies will aid in the identification of high-risk patients and inform clinical practices for monitoring and treatment of individuals with CKD.

This study is ongoing.

The CKD Biomarkers Consortium was established to pursue the discovery and validation of novel biomarkers for CKD to advance research into the causes and outcomes of the disease.

Participant criteria vary by study and the cohort(s) used for analysis.

This study is ongoing.